Comprehensive gene panel testing, one of the exciting new tools in cancer diagnostics, warrants greater scrutiny—as does a federal program aimed at speeding up the review process for proposed new medical technologies. Those are the conclusions of Yale medical experts who studied both and published a report in the JNCI: Journal of the National Cancer Institute on Sept. 18.
This article was originally published on MedicalXpress.com